Prof. Paul Stupple is a seasoned medicinal chemist with more than 20 years of experience in the global pharmaceutical industry and academia.
He has an outstanding track record of advancing projects to clinical development through progression of effective design strategies, development of exceptional teams and an enthusiastic approach to building strong multidisciplinary relationships.
Prof. Stupple has a BA and DPhil in Chemistry from the University of Oxford in the UK and spent the first decade of his career at Pfizer, UK where, as medicinal chemistry design leader with management responsibility, he provided leadership to multidisciplinary teams which delivered 6 clinical candidates of which 4 advanced to Phase I clinical trials and 2 to Phase II.
Following a subsequent move to Australia, initially to WEHI and for the past 7 years at Monash University, Prof. Stupple led the Medicinal Chemistry program at the Cancer Therapeutics CRC (CTx), an organisation that ultimately became Canthera Discovery. In this role he led a chemistry program that resulted in two of the largest preclinical licencing agreements ever made in Australia. These included two projects; the first of which was licensed to Merck, Sharp and Dohme (MSD) in 2016, and the second was licensed to Pfizer in 2018 from which its lead compound was nominated as a development candidate and is currently undergoing Phase I clinical trials.
